Non-coding RNA in the species Homo sapiens
MiR-155 is a microRNA that in humans is encoded by the MIR155 host gene or MIR155HG.[3] MiR-155 plays a role in various physiological and pathological processes.[4][5][6][7][8][9] Exogenous molecular control in vivo of miR-155 expression may inhibit malignant growth,[10][11] viral infections,[12] and enhance the progression of cardiovascular diseases.[13]
- ^ a b c GRCh38: Ensembl release 89: ENSG00000283904 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Cite error: The named reference
entrez
was invoked but never defined (see the help page).
- ^ Faraoni I, Antonetti FR, Cardone J, Bonmassar E (Jun 2009). "miR-155 gene: a typical multifunctional microRNA" (PDF). Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1792 (6): 497–505. doi:10.1016/j.bbadis.2009.02.013. PMID 19268705.
- ^ Teng G, Papavasiliou FN (Mar 2009). "Shhh! Silencing by microRNA-155". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 364 (1517): 631–637. doi:10.1098/rstb.2008.0209. PMC 2660923. PMID 19008191.
- ^ Calame K (Dec 2007). "MicroRNA-155 function in B Cells". Immunity. 27 (6): 825–827. doi:10.1016/j.immuni.2007.11.010. PMID 18093533.
- ^ Tili E, Croce CM, Michaille JJ (2009). "miR-155: on the crosstalk between inflammation and cancer". International Reviews of Immunology. 28 (5): 264–284. doi:10.1080/08830180903093796. PMID 19811312. S2CID 205589961.
- ^ O'Connell RM, Rao DS, Baltimore D (2012). "microRNA regulation of inflammatory responses". Annual Review of Immunology. 30: 295–312. doi:10.1146/annurev-immunol-020711-075013. PMID 22224773.
- ^ Elton TS, Selemon H, Elton SM, Parinandi NL (Dec 2013). "Regulation of the MIR155 host gene in physiological and pathological processes". Gene. 532 (1): 1–12. doi:10.1016/j.gene.2012.12.009. PMID 23246696.
- ^ Mattiske S, Suetani RJ, Neilsen PM, Callen DF (Aug 2012). "The oncogenic role of miR-155 in breast cancer". Cancer Epidemiology, Biomarkers & Prevention. 21 (8): 1236–1243. doi:10.1158/1055-9965.EPI-12-0173. hdl:2440/73553. PMID 22736789.
- ^ Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ (Jun 2012). "Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma". Proceedings of the National Academy of Sciences of the United States of America. 109 (26): E1695–1704. doi:10.1073/pnas.1201516109. PMC 3387084. PMID 22685206.
- ^ Wang L, Toomey NL, Diaz LA, Walker G, Ramos JC, Barber GN, Ning S (Aug 2011). "Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression". Journal of Virology. 85 (16): 8328–8337. doi:10.1128/JVI.00570-11. PMC 3147954. PMID 21680528.
- ^ Corsten MF, Papageorgiou A, Verhesen W, Carai P, Lindow M, Obad S, Summer G, Coort SL, Hazebroek M, van Leeuwen R, Gijbels MJ, Wijnands E, Biessen EA, De Winther MP, Stassen FR, Carmeliet P, Kauppinen S, Schroen B, Heymans S (Aug 2012). "MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis". Circulation Research. 111 (4): 415–425. doi:10.1161/CIRCRESAHA.112.267443. PMID 22715471.